193 related articles for article (PubMed ID: 29467389)
21. Mechanisms for luteinizing hormone induction of growth hormone gene transcription in fish model: crosstalk of the cAMP/PKA pathway with MAPK-and PI3K-dependent cascades.
Sun C; He M; Ko WK; Wong AO
Mol Cell Endocrinol; 2014 Feb; 382(2):835-50. PubMed ID: 24161589
[TBL] [Abstract][Full Text] [Related]
22. BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.
Bonaldi E; Gargiuli C; De Cecco L; Micali A; Rizzetti MG; Greco A; Borrello MG; Minna E
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072194
[No Abstract] [Full Text] [Related]
23. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
Liu D; Liu Z; Jiang D; Dackiw AP; Xing M
J Clin Endocrinol Metab; 2007 Dec; 92(12):4686-95. PubMed ID: 17911174
[TBL] [Abstract][Full Text] [Related]
24. IGF-I and vasoactive intestinal peptide (VIP) regulate cAMP-response element-binding protein (CREB)-dependent transcription via the mitogen-activated protein kinase (MAPK) pathway in pituitary cells: requirement of Rap1.
Fernández M; Sánchez-Franco F; Palacios N; Sánchez I; Cacicedo L
J Mol Endocrinol; 2005 Jun; 34(3):699-712. PubMed ID: 15956341
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAF(V600E) mutant thyroid cancer cells in 2D and 3D culture.
Ingeson-Carlsson C; Martinez-Monleon A; Nilsson M
Exp Cell Res; 2015 Nov; 338(2):127-35. PubMed ID: 26384551
[TBL] [Abstract][Full Text] [Related]
26. PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest.
Datta NS; Chen C; Berry JE; McCauley LK
J Bone Miner Res; 2005 Jun; 20(6):1051-64. PubMed ID: 15883646
[TBL] [Abstract][Full Text] [Related]
27. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
28. Cell type-specific bidirectional regulation of the glucocorticoid-induced leucine zipper (GILZ) gene by estrogen.
Tynan SH; Lundeen SG; Allan GF
J Steroid Biochem Mol Biol; 2004 Aug; 91(4-5):225-39. PubMed ID: 15336700
[TBL] [Abstract][Full Text] [Related]
29. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
30. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
31. Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas.
Levy R; Grafi-Cohen M; Kraiem Z; Kloog Y
Mol Cancer Ther; 2010 Aug; 9(8):2208-19. PubMed ID: 20682656
[TBL] [Abstract][Full Text] [Related]
32. Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells.
Sawa A; Chiba T; Ishii J; Yamamoto H; Hara H; Kamma H
Endocr J; 2017 Nov; 64(11):1115-1123. PubMed ID: 28855436
[TBL] [Abstract][Full Text] [Related]
33. Increased type 3 deiodinase expression in papillary thyroid carcinoma.
Romitti M; Wajner SM; Zennig N; Goemann IM; Bueno AL; Meyer EL; Maia AL
Thyroid; 2012 Sep; 22(9):897-904. PubMed ID: 22823995
[TBL] [Abstract][Full Text] [Related]
34. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
36. GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling.
Ayroldi E; Zollo O; Bastianelli A; Marchetti C; Agostini M; Di Virgilio R; Riccardi C
J Clin Invest; 2007 Jun; 117(6):1605-15. PubMed ID: 17492054
[TBL] [Abstract][Full Text] [Related]
37. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S
Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
[TBL] [Abstract][Full Text] [Related]
38. Podoplanin (PDPN) affects the invasiveness of thyroid carcinoma cells by inducing ezrin, radixin and moesin (E/R/M) phosphorylation in association with matrix metalloproteinases.
Sikorska J; Gaweł D; Domek H; Rudzińska M; Czarnocka B
BMC Cancer; 2019 Jan; 19(1):85. PubMed ID: 30654768
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
40. (V600E)BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism.
Baquero P; Sánchez-Hernández I; Jiménez-Mora E; Orgaz JL; Jiménez B; Chiloeches A
Cancer Lett; 2013 Jul; 335(1):232-41. PubMed ID: 23435375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]